201 related articles for article (PubMed ID: 36252563)
1. Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Perez-Paramo YX; Watson CJW; Chen G; Thomas CE; Adams-Haduch J; Wang R; Khor CC; Koh WP; Nelson HH; Yuan JM; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):54-65. PubMed ID: 36252563
[TBL] [Abstract][Full Text] [Related]
2. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and genetic biomarkers associated with nicotine dependence in Mexican smokers.
Borrego-Soto G; Perez-Paramo YX; Hernández-Cabrera F; Alvarado-Monroy FM; Borrego G; Robles-Zamora A; Lazarus P; Rojas-Martinez A
Pharmacol Res Perspect; 2023 Oct; 11(5):e01142. PubMed ID: 37787014
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in CYP2A6 and UGT1A9 genes associated with urinary nicotine metabolites in young Mexican smokers.
Borrego-Soto G; Perez-Paramo YX; Chen G; Santuario-Facio SK; Santos-Guzman J; Posadas-Valay R; Alvarado-Monroy FM; Balderas-Renteria I; Medina-Gonzalez R; Ortiz-Lopez R; Lazarus P; Rojas-Martinez A
Pharmacogenomics J; 2020 Aug; 20(4):586-594. PubMed ID: 31959879
[TBL] [Abstract][Full Text] [Related]
5. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Chen G; Giambrone NE; Lazarus P
Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
[TBL] [Abstract][Full Text] [Related]
6. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.
Chen G; Giambrone NE; Dluzen DF; Muscat JE; Berg A; Gallagher CJ; Lazarus P
Cancer Res; 2010 Oct; 70(19):7543-52. PubMed ID: 20876810
[TBL] [Abstract][Full Text] [Related]
7. Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.
Taghavi T; St Helen G; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2017 Apr; 27(4):143-154. PubMed ID: 28178031
[TBL] [Abstract][Full Text] [Related]
8. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.
Yuan JM; Nelson HH; Carmella SG; Wang R; Kuriger-Laber J; Jin A; Adams-Haduch J; Hecht SS; Koh WP; Murphy SE
Carcinogenesis; 2017 Apr; 38(4):411-418. PubMed ID: 28182203
[TBL] [Abstract][Full Text] [Related]
9. Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study.
Yuan JM; Nelson HH; Butler LM; Carmella SG; Wang R; Kuriger-Laber JK; Adams-Haduch J; Hecht SS; Gao YT; Murphy SE
Int J Cancer; 2016 May; 138(9):2161-71. PubMed ID: 26662855
[TBL] [Abstract][Full Text] [Related]
10. Effects of watercress consumption on urinary metabolites of nicotine in smokers.
Hecht SS; Carmella SG; Murphy SE
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):907-13. PubMed ID: 10548320
[TBL] [Abstract][Full Text] [Related]
11. Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.
Murphy SE; Sipe CJ; Choi K; Raddatz LM; Koopmeiners JS; Donny EC; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1093-1099. PubMed ID: 28264876
[No Abstract] [Full Text] [Related]
12. A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.
Taghavi T; Novalen M; Lerman C; George TP; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):882-891. PubMed ID: 29853480
[No Abstract] [Full Text] [Related]
13. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness.
Williams JM; Gandhi KK; Benowitz NL
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2582-9. PubMed ID: 20719908
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD).
Nasrin S; Coates S; Bardhi K; Watson C; Muscat JE; Lazarus P
Chem Res Toxicol; 2023 Feb; 36(2):177-187. PubMed ID: 36626330
[TBL] [Abstract][Full Text] [Related]
15. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
16. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.
Berg JZ; von Weymarn LB; Thompson EA; Wickham KM; Weisensel NA; Hatsukami DK; Murphy SE
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1423-31. PubMed ID: 20501767
[TBL] [Abstract][Full Text] [Related]
17. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Ho MK; Mwenifumbo JC; Al Koudsi N; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2009 Jun; 85(6):635-43. PubMed ID: 19279561
[TBL] [Abstract][Full Text] [Related]
18. Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.
Murphy SE
Chem Res Toxicol; 2017 Jan; 30(1):410-419. PubMed ID: 28092945
[TBL] [Abstract][Full Text] [Related]
19. Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies.
Giratallah HK; Chenoweth MJ; Addo N; Ahluwalia JS; Cox LS; Lerman C; George TP; Benowitz NL; Tyndale RF
Drug Alcohol Depend; 2021 Jun; 223():108708. PubMed ID: 33873029
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of Ten Urinary Nicotine Metabolites, Including 4-Hydroxy-4-(3-pyridyl) Butanoic Acid, a Product of Nicotine 2'-Oxidation, and CYP2A6 Activity in Japanese Americans, Native Hawaiians, and Whites.
von Weymarn LB; Lu X; Thomson NM; LeMarchand L; Park SL; Murphy SE
Chem Res Toxicol; 2023 Feb; 36(2):313-321. PubMed ID: 36735658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
